Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 7Genitourinary 6Myeloid 5Thoracic 4Head & Neck 3Gastrointestinal 2Breast 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Endocrine 1Dermatologic 1CNS 1

Conditions

Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene 1

Interventions

Everolimus 59lutetium Lu 177 dotatate 46Magnetic Resonance Spectroscopy 33pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 24lanreotide 23cabozantinib 22pasireotide 21gallium Ga 68 dotatate 21lenvatinib 20Etoposide 19Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18Sunitinib 17Bevacizumab 16trametinib 15dabrafenib 15Doxorubicin 143-Iodobenzylguanidine 14surufatinib 13Sorafenib 13Ipilimumab 13Thyrotropin Alfa 12Injections 12Positron Emission Tomography Computed Tomography 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pioglitazone × Endocrine × Clear all
NCT01655719 2017-10-26

Pioglitazone in Thyroid Cancers

University of Michigan

Phase 2 Completed
1 enrolled 6 charts
EndocrineHead & Neck

Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene

Data powered by HemOnc (CC BY 4.0) Colophon âš¡